2022 / Italy
2022 / Italy
Reshaping biopsy and needle-based therapy through AI-powered robotics. AI, machine learning, and robotics to help radiologists and urologists minimizing the diagnostic error and achieve a speedy and effective therapy.
HEALTH
SECTOR
EQUITY
DAYONE
Problem.
Prostate cancer is the second most common cancer in men.
In Europe, around 1 million prostate biopsies are carried out each year. Biopsy is still affected by diagnostic errors between 30% and 50%. The main sources of error are target detection and needle insertion: both operator dependent!
Solution.
A safe, accurate and repeatable robot-assisted procedure.
Improve the clinical outcome in needle based prostate biopsy procedures by using AI and robotics through target identification and planning, needle position and biopsy execution.